De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CareDx Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van CareDx is gedaald met een gemiddeld jaarlijks percentage van -48.8%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.7%. De inkomsten zijn groeide met een gemiddeld percentage van 18% per jaar.

Belangrijke informatie

-48.8%

Groei van de winst

-44.5%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	18.0%
Rendement op eigen vermogen	-60.3%
Nettomarge	-53.7%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

Sep 29

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

Aug 01

CareDx: Benefiting From Some Certainty

Jul 15

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

Apr 27

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Mar 02

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

Dec 27

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27

Opbrengsten en kosten

Hoe CareDx geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:CDNA Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	297	-160	194	76
31 Mar 24	275	-183	196	76
31 Dec 23	280	-190	201	82
30 Sep 23	297	-91	202	87
30 Jun 23	309	-84	196	90
31 Mar 23	320	-81	198	93
31 Dec 22	322	-77	196	90
30 Sep 22	319	-74	193	89
30 Jun 22	315	-69	187	86
31 Mar 22	308	-50	170	82
31 Dec 21	296	-31	152	77
30 Sep 21	276	-18	136	68
30 Jun 21	254	-9	123	61
31 Mar 21	221	-14	112	55
31 Dec 20	192	-19	103	49
30 Sep 20	169	-20	93	45
30 Jun 20	150	-19	86	41
31 Mar 20	139	-20	81	35
31 Dec 19	127	-22	75	31
30 Sep 19	115	-21	68	26
30 Jun 19	102	-39	58	21
31 Mar 19	88	-45	51	17
31 Dec 18	77	-47	45	15
30 Sep 18	66	-75	39	14
30 Jun 18	57	-69	35	13
31 Mar 18	51	-59	31	12
31 Dec 17	48	-55	33	12
30 Sep 17	47	-39	32	10
30 Jun 17	47	-29	33	7
31 Mar 17	46	-35	34	4
31 Dec 16	41	-39	32	12
30 Sep 16	36	-29	29	0
30 Jun 16	31	-28	26	0
31 Mar 16	27	-21	22	0
31 Dec 15	28	-14	21	0
30 Sep 15	29	-9	19	0
30 Jun 15	29	-4	17	0
31 Mar 15	29	0	16	0
31 Dec 14	27	1	15	0
30 Sep 14	25	0	13	0
30 Jun 14	24	-2	13	0
31 Mar 14	23	-3	11	0
31 Dec 13	22	-4	11	0

Kwaliteitswinsten: CDNA is momenteel verliesgevend.

Groeiende winstmarge: CDNA is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: CDNA is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 48.8% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van CDNA over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: CDNA is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.5% ).

Rendement op eigen vermogen

Hoge ROE: CDNA heeft een negatief Return on Equity ( -60.32% ), omdat het momenteel verliesgevend is.

CareDx Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

CareDx, Inc to Report Q2, 2024 Results on Jul 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024

CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics

CareDx, Inc Appoints Keith Kennedy as Chief Operating Officer

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too

CareDx, Inc Revises Earnings Guidance for the Full Year 2024

CareDx, Inc to Report Q2, 2024 Results on Jul 31, 2024

CareDx: Benefiting From Some Certainty

CareDx, Inc Announces New Data to Be Presented At the 2024 American Transplant Congress

Study Shows CareDx, Inc.’s HeartCare Outperforms dd-cfDNA Alone in Identifying Rejection and Patients Experienced Excellent Outcomes with Fewer Biopsies

Price target increased by 11% to US$14.40

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Executive Director exercised options to buy US$123k worth of stock.

CareDx, Inc, Annual General Meeting, Jun 13, 2024

Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge

CareDx, Inc Appoints John W. Hanna as Chief Executive Officer

CareDx, Inc Appoints Bryan Riggsbee to Its Board of Directors

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too

Full year 2023 earnings: EPS misses analyst expectations

CareDx, Inc Provides Revenue Guidance for the Full Year of 2024

CareDx, Inc to Report Q4, 2023 Results on Feb 28, 2024

Jury Rules in Favor of Natera, Inc in Patent Infringement Lawsuit Against CareDx, Inc

CareDx, Inc Provides Earnings Guidance for Fourth Quarter Ended December 31, 2023

Price target increased by 11% to US$11.80

CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry

CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents

CareDx, Inc to Report Q3, 2023 Results on Nov 08, 2023

CareDx, Inc Announces Resignation of Reginald Seeto as Chief Executive Officer

CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents

CareDx, Inc Announces Executive Changes

SEC Concludes Investigation as to CareDx and Does Not Intend to Recommend an Enforcement Action

Price target decreased by 16% to US$10.80

Consensus EPS estimates fall by 14%

Independent Director exercised options to buy US$173k worth of stock.

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareDx, Inc. Provides Revenue Guidance for the Full Year 2023

CareDx, Inc to Report Q2, 2023 Results on Aug 08, 2023

CareDx, Inc. Announces Medicare Coverage for HeartCare

Price target increased by 26% to US$12.60

CareDx, Inc (NasdaqGM:CDNA) acquired MediGO, Inc.

CareDx’s AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring

New minor risk - Share price stability

President notifies of intention to sell stock

Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price

Consensus revenue estimates fall by 13%

Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CareDx, Inc to Report Q1, 2023 Results on May 10, 2023

Consensus EPS estimates fall by 10%

Price target decreased by 22% to US$20.40

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

CareDx, Inc. Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions At the 2023 Tandem Meetings

Executive Director notifies of intention to sell stock

Executive Director notifies of intention to sell stock

Price target decreased by 7.6% to US$26.17

CareDx, Inc Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

President notifies of intention to sell stock

Executive Officer notifies of intention to sell stock

CareDx, Inc (NasdaqGM:CDNA) announces an Equity Buyback for $50 million worth of its shares.

CareDx, Inc Announces the Results of A New Study Published in Transplantation Direct

CareDx, Inc Announces Resignation of Ralph Snyderman as Director, Effective from December 31, 2022

Price target decreased to US$30.00

Third quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 3Q 2021)

Caredx, Inc., Revises Revenue Guidance for the Full Year 2022

Independent Longitudinal Study Finds Caredx’S Allosure Detects Early Signs of Rejection in Pediatric Kidney Transplant Patients

CareDx, Inc to Report Q3, 2022 Results on Nov 03, 2022

CareDx: Shaking Off First-Mover Disadvantage

Caredx, Inc Announces Transplant Patients Experience Less Pain and Fewer Adverse Events with Caredx Non-Invasive Testing Solutions

CareDx, Inc Announces Executive Changes